Rapid Minimal Residual Disease Clearance with More Stringent Age-Related Dose Criteria Improves Prognosis in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia

被引：0
|
作者：
Ishihara, T. [1 ]
Arakawa, Y. [2 ]
Miyamura, T. [3 ]
Nogami, Y. [4 ]
Ishimaru, S. [4 ,5 ]
Takachi, T. [6 ]
Yano, M. [7 ]
Sasaki, S. [8 ]
Saito, A. [9 ]
Deguchi, T. [10 ]
Hori, T. [11 ]
Yamada, T. [9 ]
Sanada, M. [9 ]
Manabe, A. [12 ]
Horibe, K.
Imamura, T. [13 ]
Tomizawa, D. [10 ]
机构：
[1] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan
[2] Saitama Childrens Med Ctr, Dept Hematol Oncol, Saitama, Japan
[3] Osaka Univ, Grad Sch Med, Dept Pediat, Suita, Osaka, Japan
[4] Natl Canc Ctr, Dept Pediat Oncol, Tokyo, Japan
[5] Princess Maxima Ctr Pediat Oncol, Trial & Data Ctr, Utrecht, Netherlands
[6] Shizuoka Childrens Hosp, Dept Hematol & Oncol, Shizuoka, Japan
[7] Kyoto City Hosp, Dept Pediat, Kyoto, Japan
[8] Hirosaki Univ, Grad Sch Med, Dept Pediat, Hirosaki, Aomori, Japan
[9] Natl Hosp Org, Nagoya Med Ctr, Clin Res Ctr, Nagoya, Aichi, Japan
[10] Natl Ctr Child Hlth & Dev, Childrens Canc Ctr, Tokyo, Japan
[11] Aichi Med Univ, Dept Pediat, Nagakute, Aichi, Japan
[12] Hokkaido Univ, Dept Pediat, Sapporo, Hokkaido, Japan
[13] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Pediat, Kyoto, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O0178
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 37 条
  • [21] Intensification of Early-Phase Therapy to Diminish the Prognostic Effect of Myeloid Antigen Expression in Infants with KMT2A-Rearranged Acute Lymphoblastic Leukemia: A Report from the JPLSG MLL-10 Trial
    Arakawa, Yuki
    Ishihara, Takashi
    Miyamura, Takako
    Deguchi, Takao
    Sanada, Masashi
    Hori, Toshinori
    Yamada, Tomomi
    Aoki, Yuki
    Ishimaru, Sae
    Takachi, Takayuki
    Yano, Mio
    Sasaki, Shinya
    Saito, Akiko M.
    Manabe, Atsushi
    Horibe, Keizo
    Imamura, Toshihiko
    Tomizawa, Daisuke
    BLOOD, 2021, 138
  • [22] Minimal residual disease in cerebrospinal fluid at diagnosis: a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia
    Biojone, Estefania
    Queiroz, Rosane De Paula
    Valera, Elvis Terci
    Odashima, Newton Satoro
    Takayanagui, Osvaldo Massaiti
    Viana, Marcos Borato
    Tone, Luiz Gonzaga
    Scrideli, Carlos Alberto
    LEUKEMIA & LYMPHOMA, 2012, 53 (01) : 89 - U184
  • [23] Characterization of KMT2A::MATR3 fusion in a patient with acute lymphoblastic leukemia and monitoring of minimal residual disease by nanoplate digital PCR
    Komatsu, Kazuyuki
    Sakaguchi, Kimiyoshi
    Shimizu, Daisuke
    Yamoto, Kaori
    Kato, Fumiko
    Miyairi, Isao
    Ogata, Tsutomu
    Saitsu, Hirotomo
    PEDIATRIC BLOOD & CANCER, 2023, 70 (04)
  • [24] A Phase 2 Study to Test the Feasibility Safe and Efficacy of the Addition of Blinatumomab to the Interfanto6 Backbone in Infants with Newly Diagnosed KMT2A-Rearranged Acute Lymphoblastic Leukemia. a Collaborative Study of the Interfant Network
    Van Der Sluis, Inge M.
    De Lorenzo, Paola
    Kotecha, Rishi Sury
    Attarbaschi, Andishe
    Escherich, Gabriele
    Nysom, Karsten
    Stary, Jan
    Ferster, Alina
    Brethon, Benoit
    Ancliff, Phillip
    Biondi, Andrea
    Valsecchi, Maria Grazia
    Pieters, Rob
    BLOOD, 2021, 138
  • [25] MINIMAL RESIDUAL DISEASE IN CEREBROSPINAL FLUID AT DIAGNOSIS: MORE INTENSIVE TREATMENT PROTOCOL WAS ABLE IN ELIMINATE THE ADVERSE PROGNOSIS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Biojone, Estefania
    Queiroz, Rosane
    Valera, Elvis
    Takayanagui, Osvaldo
    Scrideli, Carlos
    Tone, Luiz Gonzaga
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 768 - 768
  • [26] Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1
    Guest, Erin M.
    Kairalla, John A.
    Devidas, Meenakshi
    Hibbitts, Emily
    Carroll, Andrew J.
    Heerema, Nyla A.
    Kubaney, Holly R.
    August, Margaret A.
    Ramesh, Sidharth
    Yoo, Byunggil
    Farooqi, Midhat S.
    Pauly, Melinda G.
    Wechsler, Daniel S.
    Miles, Rodney R.
    Reid, Joel M.
    Kihei, Cynthia D.
    Gore, Lia
    Raetz, Elizabeth A.
    Hunger, Stephen P.
    Loh, Mignon L.
    Brown, Patrick A.
    HAEMATOLOGICA, 2024, 109 (12) : 3918 - 3927
  • [27] COMPARISON OF BONE MARROW AND PERIPHERAL BLOOD SAMPLES FOR MINIMAL RESIDUAL DISEASE MONITORING IN INFANTS WITH MLL-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA TREATED BY MLL-BABY PROTOCOL
    Tsaur, G.
    Popov, A.
    Riger, T.
    Solodovnikov, A.
    Nasedkina, T.
    Kustanovich, A.
    Aleinikova, O.
    Shorikov, E.
    Streneva, O.
    Saveliev, L.
    Fechina, L.
    HAEMATOLOGICA, 2014, 99 : 9 - 10
  • [28] Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Munster Study Group
    van Weelderen, Romy E.
    Klein, Kim
    Harrison, Christine J.
    Jiang, Yilin
    Abrahamsson, Jonas
    Arad-Cohen, Nira
    Bart-Delabesse, Emmanuelle
    Buldini, Barbara
    De Moerloose, Barbara
    Dworzak, Michael N.
    Elitzur, Sarah
    Fernandez Navarro, Jose M.
    Gerbing, Robert B.
    Goemans, Bianca F.
    de Groot-Kruseman, Hester A.
    Guest, Erin
    Ha, Shau-Yin
    Hasle, Henrik
    Kelaidi, Charikleia
    Lapillonne, Helene
    Leverger, Guy
    Locatelli, Franco
    Masetti, Riccardo
    Miyamura, Takako
    Noren-Nystrom, Ulrika
    Polychronopoulou, Sophia
    Rasche, Mareike
    Rubnitz, Jeffrey E.
    Stary, Jan
    Tierens, Anne
    Tomizawa, Daisuke
    Zwaan, C. Michel
    Kaspers, Gertjan J. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16) : 2963 - 2974
  • [29] Comparison of minimal residual disease measurement by multicolour flow cytometry and PCR for fusion gene transcripts in infants with acute lymphoblastic leukaemia with KMT2A gene rearrangements
    Popov, Alexander
    Tsaur, Grigory
    Verzhbitskaya, Tatiana
    Riger, Tatiana
    Permikin, Zhan
    Demina, Anna
    Mikhailova, Ekaterina
    Shorikov, Egor
    Arakaev, Oleg
    Streneva, Olga
    Khlebnikova, Olga
    Makarova, Olga
    Miakova, Natalia
    Fominikh, Veronika
    Boichenko, Elmira
    Kondratchik, Konstantin
    Ponomareva, Natalia
    Novichkova, Galina
    Karachunskiy, Alexander
    Fechina, Larisa
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 510 - 519
  • [30] A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1
    Guest, Erin
    Kairalla, John
    Devidas, Meenakshi
    Hibbitts, Emily
    Carroll, Andrew J.
    Heerema, Nyla A.
    Kubaney, Holly
    August, Amanda
    Pauly, Melinda
    Wechsler, Daniel
    Miles, Rodney R.
    Reid, Joel M.
    Kihei, Cynthia
    Gore, Lia
    Raetz, Elizabeth A.
    Hunger, Stephen P.
    Loh, Mignon L.
    Brown, Patrick A.
    BLOOD, 2022, 140 : 3256 - 3257
1234